• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The experience of successful treatment of -positive infant glioblastoma with entrectinib.

作者信息

Papusha Ludmila, Zaytseva Margarita, Druy Alexander, Valiakhmetova Andge, Yasko Ludmila, Salnikova Ekaterina, Shekhtman Anastasia, Karachunsky Alexander, Maschan Alexey, Hwang Eugene I, Novichkova Galina, Packer Roger J

机构信息

D. Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.

Center for Neuroscience and Behavioral Medicine, Brain Tumor Institute, Washington, District of Columbia, USA.

出版信息

Neurooncol Adv. 2021 Feb 3;3(1):vdab022. doi: 10.1093/noajnl/vdab022. eCollection 2021 Jan-Dec.

DOI:10.1093/noajnl/vdab022
PMID:33738452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7954097/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe8a/7954097/55b027df9d1e/vdab022_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe8a/7954097/55b027df9d1e/vdab022_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe8a/7954097/55b027df9d1e/vdab022_fig1.jpg

相似文献

1
The experience of successful treatment of -positive infant glioblastoma with entrectinib.恩曲替尼成功治疗阳性婴儿胶质母细胞瘤的经验。
Neurooncol Adv. 2021 Feb 3;3(1):vdab022. doi: 10.1093/noajnl/vdab022. eCollection 2021 Jan-Dec.
2
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in -Positive Acute Myeloid Leukemia.恩曲替尼（一种泛 TRK、ROS1 和 ALK 抑制剂）在阳性急性髓系白血病中的抗肿瘤活性。
Mol Cancer Ther. 2018 Feb;17(2):455-463. doi: 10.1158/1535-7163.MCT-17-0419. Epub 2017 Dec 13.
3
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).乳腺类似物分泌癌（MASC）中ETV6-NTRK3基因被鉴定后，MASC背后隐藏着什么：恩曲替尼的临床反应和获得性耐药。
Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.
4
Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.ETV6-NTRK3基因融合的分子检测可将先天性纤维肉瘤与其他儿童期梭形细胞肿瘤区分开来。
Am J Surg Pathol. 2000 Jul;24(7):937-46. doi: 10.1097/00000478-200007000-00005.
5
Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.先天性中胚层肾瘤t(12;15)与ETV6-NTRK3基因融合相关：与先天性（婴儿型）纤维肉瘤的细胞遗传学及分子关系
Am J Pathol. 1998 Nov;153(5):1451-8. doi: 10.1016/S0002-9440(10)65732-X.
6
Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues.先天性婴儿纤维肉瘤：10例临床病理研究及应用石蜡包埋组织对ETV6-NTRK3融合转录本进行分子检测
Am J Clin Pathol. 2001 Mar;115(3):348-55. doi: 10.1309/3H24-E7T7-V37G-AKKQ.
7
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.ETV6-NTRK3嵌合酪氨酸激酶引起的细胞转化及磷酸肌醇-3-激酶-Akt级联反应的激活需要c-Src。
Cancer Res. 2007 Apr 1;67(7):3192-200. doi: 10.1158/0008-5472.CAN-06-3526.
8
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.先天性纤维肉瘤中的一种新型ETV6-NTRK3基因融合
Nat Genet. 1998 Feb;18(2):184-7. doi: 10.1038/ng0298-184.
9
The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.ETV6-NTRK3基因融合编码一种嵌合蛋白酪氨酸激酶，可转化NIH3T3细胞。
Oncogene. 2000 Feb 17;19(7):906-15. doi: 10.1038/sj.onc.1203396.
10
The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.嵌合蛋白酪氨酸激酶ETV6-NTRK3在成纤维细胞转化过程中需要Ras-Erk1/2和PI3激酶-Akt信号通路的共同作用。
Cancer Res. 2001 Dec 15;61(24):8909-16.

引用本文的文献

1
CENPF interaction with PLA2G4A promotes glioma growth by modulating mTORC1 and NF-κB pathways.CENPF与PLA2G4A的相互作用通过调节mTORC1和NF-κB信号通路促进胶质瘤生长。
Cancer Cell Int. 2025 Mar 1;25(1):73. doi: 10.1186/s12935-025-03700-6.
2
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.世界卫生组织中枢神经系统肿瘤分类的分子检测：综述
JAMA Oncol. 2025 Mar 1;11(3):317-328. doi: 10.1001/jamaoncol.2024.5506.
3
Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review.

本文引用的文献

1
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.使用BRAF靶向抑制治疗BRAF V600E儿童胶质瘤的疗效
JCO Precis Oncol. 2020 May 20;4. doi: 10.1200/PO.19.00298. eCollection 2020.
2
Regression of Infantile Glioblastoma After First-Line Treatment With Larotrectinib.一线使用拉罗替尼治疗后小儿胶质母细胞瘤的消退
JCO Precis Oncol. 2020 Jun 30;4. doi: 10.1200/PO.20.00017. eCollection 2020.
3
Molecular and clinicopathologic features of gliomas harboring NTRK fusions.携带有 NTRK 融合的神经胶质瘤的分子及临床病理特征。
儿童中枢神经系统肿瘤中的罕见致癌融合：病例系列及文献综述
Cancers (Basel). 2024 Sep 30;16(19):3344. doi: 10.3390/cancers16193344.
4
Molecular Profiling and Targeted Therapies in Gliomas.脑胶质瘤的分子谱分析和靶向治疗。
Curr Neurol Neurosci Rep. 2023 Oct;23(10):627-636. doi: 10.1007/s11910-023-01299-7. Epub 2023 Oct 9.
5
Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion.ARHGEF2-NTRK融合的恶性神经胶质神经元肿瘤对恩曲替尼的反应
Neurooncol Adv. 2022 Jun 13;4(1):vdac094. doi: 10.1093/noajnl/vdac094. eCollection 2022 Jan-Dec.
6
Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory fusion glioblastoma.恩曲替尼在一例放疗难治性融合型胶质母细胞瘤成年患者中显示出持久疗效。
Neurooncol Adv. 2022 Apr 13;4(1):vdac046. doi: 10.1093/noajnl/vdac046. eCollection 2022 Jan-Dec.
Acta Neuropathol Commun. 2020 Jul 14;8(1):107. doi: 10.1186/s40478-020-00980-z.
4
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.婴儿高级别神经胶质瘤包含多个亚组，其特征为新型可靶向基因融合和良好的预后。
Cancer Discov. 2020 Jul;10(7):942-963. doi: 10.1158/2159-8290.CD-19-1030. Epub 2020 Apr 1.
5
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.ALK/ROS1/NTRK/MET 改变驱动一组婴儿半球胶质瘤。
Nat Commun. 2019 Sep 25;10(1):4343. doi: 10.1038/s41467-019-12187-5.
6
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.病例报告：拉罗替尼治疗 TRK 融合驱动的高级别胶质瘤的显著临床和影像学反应。
Br J Cancer. 2018 Sep;119(6):693-696. doi: 10.1038/s41416-018-0251-2. Epub 2018 Sep 17.